The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
The expansion makes Exothera one of the largest viral vector facilities in Europe
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Collaboration in the industry needs to be institutionalised to drive the growth.
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
Fast, flexible space allows clinical trials to start when needed. A trial can become operational, pivot or scale without traditional capital building expenditures
Subscribe To Our Newsletter & Stay Updated
